Abrocitinib is under clinical development by Pfizer and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II drugs for Dermatological Disorders have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abrocitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abrocitinib overview
Abrocitinib (Cibinqo / Freorla) is an oral small molecule that selectively acts on Janus kinase (JAK) 1. It is formulated as coated tablets, film coated tablets, tablets for oral route of administration. Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Cibinqo is indicated for the treatment of atopic dermatitis for which existing treatments are inadequate. Cibinqo is indicated for adult patients with refractory, moderate-to-severe atopic dermatitis who do not respond well to other systemic treatments (such as hormones or biological agents) or who are not suitable for the above treatments.
Abrocitinib (PF-04965842) is under development for the treatment of moderate to severe cutaneous sarcoidosis, moderate to severe atopic dermatitis, dermatological disorders, type 1 diabetes, severe fatigue from post covid condition. It is administered through oral route in the form of tablet. The drug candidate acts by targeting janus kinase 1 (JAK1). It is a new molecular entity.
It was also under development for the treatment of prurigo nodularis, chronic pruritus, lupus erythematosus and plaque psoriasis.
Pfizer overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Abrocitinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
